Overview
Holobiome is a biotechnology company harnessing the potential of the human gut microbiome to generate products that can improve health through multiple marketplaces. The Holobiome platform is powered by its Microbiome Vault – the world’s most diverse collection of human gut bacteria – and proprietary tools to understand which functions gut bacteria perform that may impact health. Holobiome’s initial focus is on targeting the gut-brain-axis, and its lead asset is a next generation probiotic targeting biology relevant for depression. Through a partnership model, Holobiome is advancing programs with major consumer, food, and pharmaceutical partners in other areas, like stress and pain. Holobiome was launched in 2018, and has been supported by a world-class investor base, as well as non-dilutive grants from the NIH and the Translational Research Institute for Space Health (TRISH), as well as several corporate partnerships. It is headquartered in Boston, MA, USA.